THDB: The winter insulin injection has obtained an overseas drug registration certificate
I'm PortAI, I can summarize articles.
THDB recently obtained the product registration certificate for insulin aspart injection issued by the Indonesian Food and Drug Authority, with registration number DKI2570600143A1. This medication is a rapid-acting insulin primarily used to control postprandial blood sugar levels. The acquisition of this registration certificate will help THDB expand its international market, enhance its brand image, and strengthen its competitiveness in emerging markets
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments